Showing results (81-90 of 91) with videos related to
Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.Ebiomedicine|January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancerManon Réda, Corentin Richard, Aurelie Bertaut, et al.Journal for Immunotherapy of Cancer|March 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancerFrancois Ghiringhelli, Richard Kim, Teresa Macarulla, et al.European Journal of Cancer (Oxford, England : 1990)|November 4, 2019
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II studyThomas Walter, Come Lepage, Romain Coriat, et al.JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.Journal of Gastrointestinal Oncology|May 18, 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinomaDavid Piquemal, Roman Bruno, Barbara Bournet, et al.The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.Lancet (London, England)|June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.Pageof 10